➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Harvard Business School
Dow
Medtronic
Boehringer Ingelheim

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IOPROMIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Iopromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00497328 ↗ COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT Completed National University Hospital, Singapore Phase 2/Phase 3 2007-08-01 This is a randomised controlled trial to investigate the efficacy of preventive regimen of hydration with high dose oral N-acetylcysteine and intravenous sodium bicarbonate pretreatment in patients with stable advanced renal insufficiency (CKD stage 3 and 4:GFR 15-60ml/min/1.73m2 calculated by Modification of Diet in Renal Disease Study equation (MDRD formula)) undergoing elective percutaneous coronary intervention (PCI).
NCT00823628 ↗ Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide Completed Seoul National University Bundang Hospital Phase 4 2009-02-01 In the treatment of coronary heart disease which is the major cause of heart attack, direct mechanical treatment with catheters such as the coronary angiography, coronary balloon intervention and stenting intervention are the mainstay of therapy in recent years. In that procedures, the investigators should use the contrast media, and it may cause kidney toxicity especially in the patients with underlying kidney disease and decreased kidney function. The investigators intended to find out which contrast agent has less kidney toxicity in the catheter based treatment of coronary arterial diseases in patients with underlying decreased kidney function
NCT00827788 ↗ Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI) Completed Ospedale della Misericordia - Grosseto Phase 4 2008-12-01 The purpose of this study is to determine the incidence of contrast induced nephropathy and myocardial tissue reperfusion following iso-osmolar iodixanol or ipo-osmolar iopromide administration in patients with acute myocardial infarction undergoing primary PCI.
NCT00827788 ↗ Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI) Completed Ospedale Le Scotte Phase 4 2008-12-01 The purpose of this study is to determine the incidence of contrast induced nephropathy and myocardial tissue reperfusion following iso-osmolar iodixanol or ipo-osmolar iopromide administration in patients with acute myocardial infarction undergoing primary PCI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iopromide

Condition Name

Condition Name for Iopromide
Intervention Trials
Contrast Induced Nephropathy 2
Kidney Failure, Chronic 2
Coronary Artery Disease 2
Neuroendocrine Carcinoma of Pancreas 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iopromide
Intervention Trials
Renal Insufficiency 3
Kidney Failure, Chronic 2
Myocardial Ischemia 2
Coronary Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iopromide

Trials by Country

Trials by Country for Iopromide
Location Trials
China 21
Korea, Republic of 3
Italy 2
United States 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iopromide
Location Trials
South Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iopromide

Clinical Trial Phase

Clinical Trial Phase for Iopromide
Clinical Trial Phase Trials
Phase 4 7
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iopromide
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iopromide

Sponsor Name

Sponsor Name for Iopromide
Sponsor Trials
Bayer 3
Seoul National University Hospital 2
Medical University of South Carolina 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iopromide
Sponsor Trials
Other 12
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Mallinckrodt
Merck
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.